<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551005</url>
  </required_header>
  <id_info>
    <org_study_id>01036</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-01036</secondary_id>
    <secondary_id>CDR0000570381</secondary_id>
    <nct_id>NCT00551005</nct_id>
  </id_info>
  <brief_title>Etoposide and Celecoxib in Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Trial of Oral Etoposide in Combination With Celecoxib in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Etoposide and celecoxib may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth. Giving more than 1 drug may be an effective treatment for&#xD;
      advanced cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when&#xD;
      given together with etoposide in treating patients with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To describe the toxicities of the combination of oral etoposide at 50 mg daily with&#xD;
           escalating doses of celecoxib in patients with advanced malignancies.&#xD;
&#xD;
        -  To evaluate the effects of the combination of etoposide and celecoxib on plasma levels&#xD;
           of vascular endothelial growth factor.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of celecoxib.&#xD;
&#xD;
      In course 1, patients receive oral etoposide once daily on days 1-35 and oral celecoxib twice&#xD;
      daily on days 8-35. In all subsequent courses, patients receive oral etoposide once daily and&#xD;
      oral celecoxib twice daily on days 1-28. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline, periodically during treatment, and at time of tumor&#xD;
      progression. Samples are analyzed for vascular endothelial growth factor levels by&#xD;
      enzyme-linked immunosorbent assay and stored for future analysis of circulating DNA of&#xD;
      angiogenic biomarkers by polymerase chain reaction assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to failure</measure>
  </primary_outcome>
  <enrollment type="Actual">58</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of a malignant disease for which no&#xD;
             satisfactory treatment exists at the time of enrollment&#xD;
&#xD;
          -  Patients with brain metastases which at the time of study enrollment are controlled&#xD;
             and do not require treatment with corticosteroids are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy â‰¥ 3 months&#xD;
&#xD;
          -  ANC &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Serum bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2.0 times upper limit of normal (unless clearly due to the presence of&#xD;
             tumor)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Patient must be capable of understanding the nature of the trial and must give written&#xD;
             informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Unstable or severe intercurrent medical conditions or active, uncontrolled infection&#xD;
&#xD;
          -  History of allergic reactions to non-steroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  History of bleeding peptic ulcer within the past 3 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Recovered from all prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Concurrent aspirin for cardiovascular indications allowed&#xD;
&#xD;
          -  More than 2 weeks since prior and no other concurrent NSAIDs&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Had radiotherapy or chemotherapy within 3 weeks (nitrosoureas or mitomycin C within 6&#xD;
             weeks) prior to anticipated first day of dosing&#xD;
&#xD;
          -  Undergoing concurrent therapy with other investigational agents or antineoplastic&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Przemyslaw W. Twardowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

